Unprecedented Phase 3 Clinical Milestones in Cutaneous Melanoma
Comprehensive findings from a landmark Phase 3 trial encompassing over 1,100 late-stage melanoma patients delivered the most robust clinical validation to date for personalized cancer vaccines. The investigational mRNA candidate, scientifically termed intismeran autogene, co-administered alongside Merck's blockbuster PD-1 inhibitor Keytruda, demonstrated a statistically compelling 42% reduction in recurrence or mortality relative to standard single-agent Keytruda therapy.
The dual-therapy protocol simultaneously decreased the clinical risk of distant metastatic spread by 38% across the two-year post-resection observation window. Longitudinal patient tracking confirmed that 82.2% of individuals receiving the vaccine combination remained completely disease-free at 24 months, compared with 70% in the active Keytruda monotherapy control cohort.
This is highly statistically significant. It is not by chance.
















